Articles

‘Modulating’ tumor treatment

Albumedix and NYU School of Medicine team up to target novel cellular pathways in oncology
Written byIlene Schneider
| 3 min read

COPENHAGEN, Denmark—While there have been significant advancements in treatment options, cancer is still one of the leading causes of morbidity and mortality worldwide. Attempting to increase the understanding of the underlying tumor biology in patients, Albumedix—a fully owned subsidiary of Novozymes A/S—has entered into a collaborative research agreement with the New York University (NYU) School of Medicine to explore the potential of novel applications of Albumedix’s albumin-based drug delivery platform, Veltis, to modulate immune pathways discovered at NYU.

The Veltis platform optimizes drug dosing through its ability to control dose size and frequency as well as drug loading. These effects are achieved using recombinant human albumin and albumin variants implemented by genetic fusion or chemical conjugation to drug candidates.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.